Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23454359 | 0.77 | MAPK14 (0.33) | CYP1A2MAPK14 | |
| SCHEMBL23454371 | 0.73 | DGAT1 (0.31) | CYP1A2MAPK14 | |
| SCHEMBL23454241 | 0.73 | DGAT1 (0.31) | CYP1A2MAPK14 | |
| SCHEMBL23454243 | 0.73 | DGAT1 (0.31) | CYP1A2MAPK14 | |
| SCHEMBL23571599 | 0.68 | MEN1 (0.45) | CYP1A2SCN5AMAPK14APP | |
| SCHEMBL14956790 | 0.67 | PDE2A (0.35) | CYP1A2SCN5AMAPK14 | |
| SCHEMBL20203997 | 0.67 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL23950805 | 0.66 | SCN5A (0.50) | CYP1A2SCN5AMAPK14 | |
| SCHEMBL20204041 | 0.65 | CYP1A2 (0.47) | CYP1A2SCN5AMAPK14 | |
| SCHEMBL23116041 | 0.65 | CYP1A2 (0.38) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250145629-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3548033-B1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240043433-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11505554-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200377507-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377507-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | SCN1A, SCN5A, SCN3A | CYP1A2 2190/4885SCN5A 2/4885MAPK14 2954/4885 |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | CYP1A2 1553/4885SCN5A 3/4885MAPK14 2971/4885 |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN5A | CYP1A2 938/4885SCN5A 3/4885MAPK14 2681/4885 |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885MAPK14 4405/4885 |
| US-11505554-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN1B | CYP1A2 923/4885SCN5A 4/4885MAPK14 2679/4885 |
| US-20250145629-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885MAPK14 4124/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885MAPK14 4405/4885 |
| US-20240043433-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885MAPK14 4124/4885 |
| US-20210171530-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885MAPK14 4124/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | CYP1A2 2127/4885SCN5A 24/4885MAPK14 4236/4885 |
| US-20200377507-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | CYP1A2 2306/4885SCN5A 6/4885MAPK14 2933/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885MAPK14 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.